Last reviewed · How we verify
NCT06222385: BRAIN3
Applied Cognition Benchmarking Study
NA trial testing Device measurements during overnight sleep and morning wake in Healthy in 34 participants. Completed in 8 June 2023.
8 June 2023
Quick facts
| Lead sponsor | Applied Cognition |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | diagnostic |
| Enrollment | 34 |
| Start date | 7 November 2022 |
| Primary completion | 8 June 2023 |
| Estimated completion | 8 June 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Device measurements during overnight sleep and morning wake
- Device measurements during overnight wake and morning sleep
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Applied Cognition — full company profile →
Who can join
Adults 55 to 65, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a cross-over randomized study to validate the Sponsor investigational medical device against measurements of glymphatic function from MRI-based neuroimaging, EEG, blood biomarkers and cognitive tests in healthy older volunteers.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
A wireless device for continuous measurement of brain parenchymal resistance tracks glymphatic function in humans.
Dagum P, Giovangrandi L, Levendovszky SR, Winebaum JJ, et al · · 2025 · cited 17× · PMID 40425804 · DOI 10.1038/s41551-025-01394-9 -
The glymphatic system clears amyloid beta and tau from brain to plasma in humans.
Dagum P, Elbert DL, Giovangrandi L, Singh T, et al · · 2026 · cited 3× · PMID 41593094 · DOI 10.1038/s41467-026-68374-8
Verify or expand the search:
- PubMed search for NCT06222385
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Applied Cognition trials
Trials by the same sponsor.
- NCT07432997 — Pharmacological Enhancement of Glymphatic Function in Humans · Phase 1, PHASE2 · completed
- NCT06060054 — Continuous Measurement of Glymphatic Activity in the Human Brain During Sleep-Wake States · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06222385 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Applied Cognition
- Last refreshed: 24 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06222385.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing